As of Wednesday close, AbbVie Inc.’s (NYSE:ABBV) stock was up $0.73, moving up 0.49 percent to $148.32. The average number of shares traded per day over the past five days has been 3,394,840 shares. 3 times new highs have been achieved over the past 5 days, with a $1.24 gain in that time frame. In the last twenty days, the average volume was 3,774,495, while in the previous 50 days, it was 5,168,990.
Since last month, ABBV stock retreated -0.15%. Shares of the company fell to $145.94 on 08/23/23, the lowest level in the past month. A 52-week high of $168.11 was reached on 01/06/23 after having rallying from a 52-week low of $130.96. Since the beginning of this year, ABBV’s stock price has dropped by -8.22% or -$13.29, and marked a new high 4 times. However, the stock has declined by -11.77% since its 52-week high.
ABBV stock investors should be aware that AbbVie Inc. (ABBV) stock had its last reported insider trading activity 30 days ago on Aug 01. GONZALEZ RICHARD A, the CHAIRMAN OF THE BOARD AND CEO of the company, disposed of 60,000 shares for $148.58 on Aug 01. It resulted in a $8,914,800 divestment by the insider. GONZALEZ RICHARD A sold 18,500 shares at an average price of $149.15 on Jul 31. The insider now owns 625,294 shares following the transaction. On Apr 25, SVP, US COMMERCIAL OPERATIONS Sorg Elaine K. sold 6,130 shares at $165.00 apiece. The transaction was valued at $1,011,450.
Valuation Metrics
Right now, AbbVie Inc. (ABBV) has a P/E ratio of about 30.51. The stock’s beta is 0.55. Besides these, the trailing price-to-sales (P/S) ratio of 4.67, the price-to-book (PB) ratio of 20.37, and the price-to-cash flow ratio of 10.55 may also be considered.
The latest dividend of $1.48 per share was paid out, remained unchanged from last year’s $1.48. On Friday October 28 2022, a $0.07 dividend increase was announced.
Financial Health
In the three months ended June 29, AbbVie Inc.’s quick ratio stood at 0.80, while its current ratio was 0.90, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 4.34, and the total debt-to-equity ratio was 4.74. On the profitability front, the trailing twelve-month gross margin is 70.50% percent. In the year ended June 29, EBITDA margin amounted to 53.52%, whereas operating margins totaled 31.00%. Based on annual data, ABBV earned $40.64 billion in gross profit and brought in $58.05 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 20.50%. Return on equity (ROE) for the past 12 months was 58.20%.
In AbbVie Inc.’s quarter-end financial report for June 29, it reported total debt of $55.81 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ABBV’s revenue fell -5.18% to $12.22 billion during the quarter, while net income inched up to $13.87 billion. While analysts expected AbbVie Inc. to report $2.81 quarterly earnings, the actual figure was $2.91 per share, beating the consensus estimate by 3.60%. During the quarter, the company generated $6.77 billion in EBITDA. The liabilities of AbbVie Inc. were 122.47 billion at the end of its most recent quarter ended June 29, and its total debt was $61.39 billion. The value of shareholders’ equity is $1.77 billion.
Technical Picture
This quick technical analysis looks at AbbVie Inc.’s (ABBV) price momentum. With a historical volatility rate of 8.70%, the RSI 9-day stood at 50.87% on 30 August.
With respect to its five-day moving average, the current AbbVie Inc. price is up by +0.84% percent or $1.24. At present, ABBV shares trade -0.71% below its 20-day simple moving average and -8.19% percent below its 100-day simple moving average. However, the stock is currently trading approximately +7.62% above its SMA50 and -0.94% below its SMA200.
Stochastic coefficient K was 24.02% and Stochastic coefficient D was 17.90%, while ATR was 2.09. Given the Stochastic reading of 31.07% for the 14-day period, the RSI (14) reading has been calculated as 54.04%. As of today, the MACD Oscillator reading stands at -0.25, while the 14-day reading stands at -1.54.
Analyst Ratings
William Blair launched its rating on AbbVie Inc. (NYSE: ABBV) to a Mkt perform in a note to investors on July 25, 2023. AbbVie Inc. (ABBV) has been rated Overweight by analysts. According to 0 brokerage firms, ABBV is a sell, and 13 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate AbbVie Inc. stock as buy, with 14 recommending it as overweight.
With a median target price of $165.00, the current consensus forecast for the stock is $135.00 – $205.00. Based on these forecasts, analysts predict AbbVie Inc. (ABBV) will achieve an average price target of $167.60.
